Search

Your search keyword '"Joo Pin Foo"' showing total 3 results
Start Over Author "Joo Pin Foo" Language english
3 results on '"Joo Pin Foo"'

1. The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea

Author

Sharon H. Chou, Athanasios D. Anastasilakis, Christos S. Mantzoros, Stergios A. Polyzos, and Joo-Pin Foo

Subjects
Adult, Genetic Markers, Leptin, medicine.medical_specialty, Adolescent, Hormone Replacement Therapy, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Parathyroid hormone, Hot Topics in Translational Endocrinology, Biochemistry, Bone remodeling, Metreleptin, chemistry.chemical_compound, Young Adult, Endocrinology, Osteoprotegerin, Double-Blind Method, Internal medicine, medicine, Humans, Amenorrhea, Adaptor Proteins, Signal Transducing, Bone mineral, biology, business.industry, Biochemistry (medical), RANK Ligand, Fibroblast Growth Factors, Fibroblast Growth Factor-23, Treatment Outcome, chemistry, RANKL, Parathyroid Hormone, Bone Morphogenetic Proteins, biology.protein, Sclerostin, Intercellular Signaling Peptides and Proteins, Female, business, Hypothalamic Diseases
Abstract

Recombinant leptin (metreleptin) treatment restores bone mineral density in women with hypothalamic amenorrhea (HA), a condition characterized by hypoleptinemia, which has adverse impact on bone health.The objective of the study was to investigate how metreleptin exerts its positive effect on bone metabolism in humans.This was a randomized, double-blinded, placebo-controlled study.The study was conducted at Beth Israel Deaconess Medical Center (Boston, Massachusetts).Women (n = 18) with HA and hypoleptinemia for at least 6 months were randomized to receive either metreleptin or placebo for 36 weeks. Serum samples were obtained at baseline and 12, 24, and 36 weeks of treatment.Circulating levels of leptin, intact PTH (iPTH), receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), sclerostin, dickkopf-1, and fibroblast growth factor-23.Metreleptin administration significantly increased leptin levels throughout the treatment period (P = .001). iPTH decreased over the 36 weeks of treatment (P = .01). There was a trend toward a decrease in serum RANKL and increase in serum OPG in the metreleptin-treated group. The RANKL to OPG ratio was significantly decreased within the metreleptin (P = .04) but not the placebo group. Metreleptin had no effect on serum sclerostin, dickkopf-1, and fibroblast growth factor-23.Metreleptin treatment over 36 weeks decreases iPTH and RANKL to OPG ratio levels in hypoleptinemic women with HA.

Published
2014

2. Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations

Author

Ole-Petter R. Hamnvik, Christos S. Mantzoros, and Joo-Pin Foo

Subjects
Male, medicine.medical_specialty, Anorexia Nervosa, business.industry, Endocrinology, Diabetes and Metabolism, Hypothalamic amenorrhea, Bone health, Article, Bone Diseases, Metabolic, Endocrinology, Sex Factors, Anorexia nervosa (differential diagnoses), Bone Density, Internal medicine, medicine, Humans, Female, business, Psychiatry, Amenorrhea, Hypothalamic Diseases
Published
2012

3. Telehealth for improved glycaemic control in patients with poorly controlled diabetes after acute hospitalization – a preliminary study in Singapore.

Author

Wai Leng, Chow, Jundong, Jiang, Li Wei, Cho, Joo Pin, Foo, Kwong Ming, Fock, and Chen, Richard

Subjects
DISEASE management, TELEMEDICINE, TREATMENT of diabetes, HOSPITAL care, GLYCEMIC index
Abstract

We evaluated a disease management and education programme delivered via telephone support (TS) to patients with poorly controlled diabetes (HbA1c >7%). All eligible patients were invited to participate in the programme, which involved education on lifestyle modification and disease management delivered via three scheduled monthly calls by trained nurses. Patients who declined or could not be contacted acted as the controls (usual care, UC). A per protocol analysis was conducted using a mixed effect model for two subgroups with different baseline HbA1c levels (i.e. baseline HbA1c <8.0% and HbA1c ≥8.0%). A total of 2646 patients with diabetes were eligible for enrolment. Of these, 1391 participants had HbA1c measurements available. The study comprised 633 patients (46%) who completed the programme (TS), 598 (43%) who were not contactable or refused to participate at the first telephone call (UC) and 160 patients who dropped out. In the patients with HbA1c ≥8%, TS reduced the adjusted mean HbA1c by 0.38% (P = 0.022) but the reduction in diabetes-related admissions (4.2% lower adjusted mean admission rate) was not significant. In patients with HbA1c <8%, TS had no additional effect on glycaemic control or diabetes-related admission. Telephone support appeared effective in improving glycaemic control in patients with poor diabetes control. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results